Literature DB >> 8789856

The surgical removal of subfoveal choroidal neovascularization. Ingrowth site as a predictor of visual outcome.

N S Melberg1, M A Thomas, D B Burgess.   

Abstract

PURPOSE: The authors determine the significance of location of the ingrowth site of subfoveal choroidal neovascularization (CNV) as a preoperative indicator of postsurgical visual acuity.
DESIGN: A retrospective review is given of preoperative fluorescein angiograms and color fundus photographs for 84 eyes with subfoveal CNV due to the following etiologies: presumed ocular histoplasmosis syndrome (POHS) = 67 eyes; multifocal choroiditis = 9 eyes; not identifiable. If identifiable, the ingrowth site was further classified as extrafoveal, juxtafoveal, or subfoveal. Correlations between CNV ingrowth site location and postoperative visual acuity were made.
RESULTS: The ingrowth site for subfoveal CNV was identifiable preoperatively in 60 eyes (71%). Of 31 eyes with an extrafoveal ingrowth site, 18 (60%) had a final visual acuity of 20/40 or better. Of 12 eyes with a juxtafoveal ingrowth site and 18 eyes with a subfoveal ingrowth site, only 2 (7%) had a final visual acuity of 20/40 or better. If the ingrowth site was not identifiable or identifiable and subfoveal in location (N = 42), 76% of eyes had a final visual acuity of 20/200 or worse.
CONCLUSION: The ingrowth site of subfoveal CNV can be identified in the majority of eyes with POHS, multifocal choroiditis, or idiopathic membranes. A significant number of subfoveal CNV will have an extrafoveal ingrowth site. Eyes with an extrafoveal ingrowth site have a favorable visual prognosis after the surgical removal of the CNV. If the ingrowth site is subfoveal or not identifiable, the visual prognosis after surgery is guarded.

Entities:  

Mesh:

Year:  1996        PMID: 8789856     DOI: 10.1097/00006982-199616030-00002

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Choroidal neovascularization in 36 eyes of children and adolescents.

Authors:  P Rishi; A Gupta; E Rishi; B J Shah
Journal:  Eye (Lond)       Date:  2013-07-26       Impact factor: 3.775

2.  Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9.

Authors:  Barbara S Hawkins; Neil M Bressler; Susan B Bressler; Frederick H Davidorf; John C Hoskins; Marta J Marsh; Päivi H Miskala; Maryann Redford; Paul Sternberg; Matthew A Thomas; Cynthia A Toth
Journal:  Arch Ophthalmol       Date:  2004-11

3.  One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration.

Authors:  A Abdel-Meguid; A Lappas; K Hartmann; F Auer; N Schrage; G Thumann; B Kirchhof
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

4.  Neovascular ingrowth site photothrombosis in choroidal neovascularization associated with retinal pigment epithelial detachment.

Authors:  Rogério A Costa; Karolinne M Rocha; Daniela Calucci; José A Cardillo; Michel E Farah
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-19       Impact factor: 3.117

5.  Choroidal neovascularization in 111 eyes of children and adolescents.

Authors:  Pukhraj Rishi; Rekha Priya Kalluri Bharat; Ekta Rishi; Muna Bhende; Jyotirmay Biswas; Arshee Ahmed; Sridharan Sudharshan
Journal:  Int Ophthalmol       Date:  2021-08-23       Impact factor: 2.031

6.  Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis.

Authors:  Pukhraj Rishi; Anusha Venkataraman; Ekta Rishi
Journal:  Indian J Ophthalmol       Date:  2011 Jan-Feb       Impact factor: 1.848

7.  Transition to a novel advanced integrated vitrectomy platform: comparison of the surgical impact of moving from the Accurus vitrectomy platform to the Constellation Vision System for microincisional vitrectomy surgery.

Authors:  Timothy G Murray; Andrew J Layton; Kuo B Tong; Michael Gittelman; Azeema Latiff; Daniel Gologorsky; Michael M Vigoda
Journal:  Clin Ophthalmol       Date:  2013-02-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.